Obinutuzumab
- Generic Name
- Obinutuzumab
- Brand Names
- Gazyva, Gazyvaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 949142-50-1
- Unique Ingredient Identifier
- O43472U9X8
- Background
Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Le...
- Indication
Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
- Associated Conditions
- Refractory Follicular Lymphoma, Previously untreated Chronic lymphocytic leukemia
- Associated Therapies
- -
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Acepodia Biotech, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT05653271
- Locations
- 🇺🇸
AdventHealth Orlando, Orlando, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT05627557
- Locations
- 🇺🇸
Memorial Healthcare System, Hollywood, Florida, United States
🇺🇸Children's Healthcare of Atlanta Center for Advanced Pediatrics, Atlanta, Georgia, United States
🇺🇸Nicklaus Children's Hospital, Miami, Florida, United States
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
- Conditions
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT05536349
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 65
- Registration Number
- NCT05533775
- Locations
- 🇧🇷
Hospital Erasto Gaertner, Curitiba, Brazil
🇧🇷GRAACC - Grupo de Apoio ao Adolescente e a Crianca com Cancer, Sao Paulo, Brazil
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden
- Conditions
- Interventions
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 98
- Registration Number
- NCT05387616
- Locations
- 🇩🇪
Carl-Thiem-Klinikum Cottbus gGmbH, Cottbus, Germany
🇩🇪Universitätsklinikum Jena, Jena, Germany
🇩🇪Charité Campus Benjamin Franklin, Berlin, Germany
PR3-AAV Resilient Remission or PRRR
- Conditions
- Interventions
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 6
- Registration Number
- NCT05376319
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Mayo Clinic Rochester, Rochester, Minnesota, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT05364424
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center UCI, Orange, California, United States
🇺🇸Memorial Cancer Institute at Memorial West, Pembroke Pines, Florida, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2024-03-15
- Target Recruit Count
- 52
- Registration Number
- NCT05336812
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 605
- Registration Number
- NCT05326308
- Locations
- 🇩🇪
Lübecker Onkologische Schwerpunktpraxis, Lübeck, Schleswig-Holstein, Germany
🇦🇹Universitätsklinikum Salzburg, Klinik für Innere Medizin III, Salzburg, Austria
Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL
- Conditions
- Interventions
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2022-04-19
- Target Recruit Count
- 25
- Registration Number
- NCT05322733
- Locations
- 🇨🇳
Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjin, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.